Humana (NYSE:HUM) PT Lowered to $575.00 at JPMorgan Chase & Co.

Humana (NYSE:HUM) had its price target cut by JPMorgan Chase & Co. from $593.00 to $575.00 in a research report sent to investors on Friday, Benzinga reports. They currently have a neutral rating on the insurance provider’s stock.

Several other equities analysts have also recently commented on the stock. TD Cowen lowered their price target on shares of Humana from $616.00 to $613.00 and set an outperform rating on the stock in a report on Tuesday, August 15th. Royal Bank of Canada boosted their target price on Humana from $594.00 to $599.00 and gave the company an outperform rating in a research note on Thursday, November 2nd. Cantor Fitzgerald reaffirmed an overweight rating and set a $597.00 price target on shares of Humana in a research note on Thursday, November 2nd. Sanford C. Bernstein lowered their price target on Humana from $599.00 to $579.00 in a research note on Tuesday, October 10th. Finally, Stephens cut their price objective on shares of Humana from $575.00 to $570.00 and set an overweight rating on the stock in a research report on Thursday, November 2nd. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Humana currently has a consensus rating of Moderate Buy and an average price target of $590.28.

Humana Trading Up 0.7 %

Shares of HUM opened at $501.79 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. Humana has a 1-year low of $423.29 and a 1-year high of $558.04. The stock has a market capitalization of $61.78 billion, a P/E ratio of 20.80, a P/E/G ratio of 1.33 and a beta of 0.61. The business’s 50-day moving average price is $497.71 and its 200 day moving average price is $485.08.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 1st. The insurance provider reported $7.78 EPS for the quarter, beating the consensus estimate of $7.15 by $0.63. Humana had a net margin of 2.95% and a return on equity of 21.03%. The business had revenue of $26.42 billion during the quarter, compared to the consensus estimate of $25.57 billion. During the same quarter in the prior year, the firm earned $6.88 EPS. The firm’s quarterly revenue was up 15.9% on a year-over-year basis. Analysts expect that Humana will post 28.28 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 0.71%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio (DPR) is presently 14.68%.

Institutional Trading of Humana

Several institutional investors have recently made changes to their positions in the business. Sunbelt Securities Inc. bought a new position in Humana during the first quarter worth about $28,000. WFA of San Diego LLC acquired a new position in shares of Humana in the 2nd quarter worth approximately $29,000. Gradient Investments LLC boosted its stake in Humana by 50.0% in the 2nd quarter. Gradient Investments LLC now owns 69 shares of the insurance provider’s stock valued at $31,000 after buying an additional 23 shares in the last quarter. Larson Financial Group LLC grew its position in Humana by 81.0% in the second quarter. Larson Financial Group LLC now owns 76 shares of the insurance provider’s stock valued at $34,000 after acquiring an additional 34 shares during the period. Finally, Baystate Wealth Management LLC raised its stake in Humana by 84.1% during the second quarter. Baystate Wealth Management LLC now owns 81 shares of the insurance provider’s stock worth $37,000 after acquiring an additional 37 shares in the last quarter. 91.86% of the stock is currently owned by institutional investors and hedge funds.

Humana Company Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.